|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"azuma m"
Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2021-11-18T04:58:07Z |
Increased prevalence of interleukin-17-producing CD4 + tumor infiltrating lymphocytes in human oral squamous cell carcinoma
|
Lee J.-J; Chang Y.-L; Lai W.-L; JENG-YUH KO; Kuo M.Y.-P; Chiang C.-P; Azuma M; Chen C.-W; Chia J.-S. |
| 臺大學術典藏 |
2021-11-15T07:48:30Z |
Increased prevalence of interleukin-17-producing CD4 + tumor infiltrating lymphocytes in human oral squamous cell carcinoma
|
Lee J.-J; Chang Y.-L; Lai W.-L; JENG-YUH KO; Kuo M.Y.-P; Chiang C.-P; Azuma M; Chen C.-W; Chia J.-S. |
| 臺大學術典藏 |
2021-07-07T01:46:55Z |
Increased prevalence of interleukin-17-producing CD4 + tumor infiltrating lymphocytes in human oral squamous cell carcinoma
|
JANG-JAER LEE; Chang Y.-L.; Lai W.-L.; Ko J.-Y.; Kuo M.Y.-P.; Chiang C.-P.; Azuma M.; Chen C.-W.; Chia J.-S. |
| 臺大學術典藏 |
2021-07-05T05:42:08Z |
Increased prevalence of interleukin-17-producing CD4 + tumor infiltrating lymphocytes in human oral squamous cell carcinoma
|
Lee J.-J.; Chang Y.-L.; Lai W.-L.; Ko J.-Y.; YEN-PING KUO; Chiang C.-P.; Azuma M.; Chen C.-W.; Chia J.-S. |
| 臺大學術典藏 |
2020-04-21T03:51:57Z |
63Cu NQR evidence of dimensional crossover to anisotropic 2d regime in S = 1/2Three-Leg Ladder Sr2Cu3O5
|
Thurber, K. R.; Imai, T.; Saitoh, T.; Azuma, M.; Takano, M.; Chou, F. C. |
| 國立成功大學 |
2019 |
Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (a
|
Boku, N.;Ryu, M.-H.;Kato, Kato K.;Chung, H.C.;Minashi, K.;Lee, K.-W.;Cho, H.;Kang, W.K.;Komatsu, Y.;Tsuda, M.;Yamaguchi, K.;Hara, Hara H.;Fumita, S.;Azuma, M.;Chen, L.-T.;Kang, Y.-K. |
| 國立成功大學 |
2019 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
|
Kato, Kato K.;Satoh, T.;Muro, K.;Yoshikawa, T.;Tamura, Tamura T.;Hamamoto, Y.;Chin, K.;Minashi, K.;Tsuda, M.;Yamaguchi, K.;Machida, N.;Esaki, T.;Goto, M.;Komatsu, Y.;Nakajima, T.E.;Sugimoto, N.;Yoshida, K.;Oki, E.;Nishina, T.;Tsuji, A.;Fujii, H.;Kunieda, Kunieda K.;Saitoh, Saitoh S.;Omuro, Y.;Azuma, M.;Iwamoto, Y.;Taku, K.;Fushida, S.;Chen, L.-T.;Kang, Y.-K.;Boku, N. |
| 國家衛生研究院 |
2018-12-19 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase 2 trial (AT
|
Boku, N;Ryu, MH;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2018-12-01 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens
|
Kato, K;Satoh, T;Muro, K;Yoshikawa, T;Tamura, T;Hamamoto, Y;Chin, K;Minashi, K;Tsuda, M;Yamaguchi, K;Machida, N;Esaki, T;Goto, M;Komatsu, Y;Nakajima, TE;Sugimoto, N;Yoshida, K;Oki, E;Nishina, T;Tsuji, A;Fujii, H;Kunieda, K;Saitoh, S;Omuro, Y;Azuma, M;Iwamoto, Y;Taku, K;Fushida, S;Chen, LT;Kang, YK;Boku, N |
| 國家衛生研究院 |
2017-09 |
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
|
Kang, YK;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Boku, N;Chen, LT |
Showing items 1-10 of 12 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
